Patient-specific HLA class II-tumor neoantigen complex (HLA-II-neoantigen)

Patient-specific HLA class II-tumor neoantigen complexes are specialized molecular assemblies consisting of a patient's unique Human Leukocyte Antigen (HLA) class II molecule (HLA-DR, -DQ, or -DP) and a peptide fragment derived from a tumor-specific somatic mutation, known as a neoantigen (Schumacher & Schreiber, 2015). These complexes are primarily expressed on the surface of professional antigen-presenting cells, such as dendritic cells, where they serve as the primary signal for the activation of CD4+ T helper cells (Blass & Ott, 2021). The recognition of these neoantigens is a cornerstone of personalized cancer immunotherapy because neoantigens are entirely absent from healthy tissues, offering a high degree of tumor specificity and reducing the risk of off-target toxicity (Sahin et al., 2017). Therapeutic strategies targeting these complexes include personalized mRNA vaccines, such as mRNA-4157, and TCR-engineered T cell therapies designed to recognize the specific HLA-II-neoantigen pairing (Draper et al., 2021). By activating CD4+ T cells, these therapies help orchestrate a robust immune response, facilitating the recruitment of cytotoxic CD8+ T cells and promoting long-term anti-tumor immunity (Ott et al., 2017).

Other names

MHC class II-neoantigen complexHLA class II-restricted neoepitopePatient-specific neoantigen-HLA-II complexNeoantigen-MHC-II complexTumor-specific HLA-II-peptide complex

Stimulation of CD4+ T helper cells through the recognition of tumor-specific mutant peptides presented by HLA class II molecules, leading to enhanced anti-tumor immunity and support for cytotoxic T cell responses (Schumacher & Schreiber, 2015).